Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer
Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast CancerПодробнее
Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBCПодробнее
Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast CancerПодробнее
Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast CancerПодробнее
Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее
Dr. Sara Tolaney on Adjuvant T-DM1 Vs Paclitaxel and Trastuzumab for Stage I HER2+ Breast CancerПодробнее
Dr. Sara Tolaney on Adjuvant Cisplatin and Radiation for Triple-Negative Breast CancerПодробнее
The OncoAlert Colloquium Day 3 Breast CancerПодробнее
The OncoAlert Colloquium Day 3 Breast CancerПодробнее
Systemic therapy in operable HER2 positive breast cancerПодробнее
CONTESSA: tesataxel in HR+ breast cancerПодробнее
Evaluating the Role of Neoadjuvant Endocrine Therapy in Breast CancerПодробнее
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast CancerПодробнее
Neoadjuvant T-DM1 in Early-Stage HER2+ Breast CancerПодробнее
Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast CancerПодробнее
HER2 Assessment in Breast CancerПодробнее
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее
Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast CancerПодробнее
The OncoAlert Colloquium Day 3 (Breast Cancer)Подробнее
Updates on managing HER2-positive early breast cancerПодробнее
